Oramed Pharmaceuticals Inc.

ORMP · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income$48,395$13,288-$7,642-$10,189
Dep. & Amort.$31$30$30$31
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$0$0
Change in WC$9,843-$2,659-$1,574$27
Other Non-Cash-$60,256-$14,228$5,667$8,196
Operating Cash Flow-$1,987-$3,569-$3,519-$1,935
Investing Activities
PP&E Inv.-$0-$4-$3-$11
Net Acquisitions$0$0$0$0
Inv. Purchases-$5,239-$62,718-$8,444-$12,164
Inv. Sales/Matur.$44,346$9,677$32,063$28,004
Other Inv. Act.-$267-$1,958$0-$65
Investing Cash Flow$38,840-$55,004$23,616$15,764
Financing Activities
Debt Repay.$0$0$0-$187
Stock Issued$0$0$0$0
Stock Repurch.-$393-$373$0-$1,198
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0-$2
Financing Cash Flow-$393-$373$0-$1,387
Forex Effect-$78$226-$1-$126
Net Chg. in Cash$36,382-$58,719$20,096$12,316
Supplemental Information
Beg. Cash$15,797$74,516$54,420$42,104
End Cash$52,179$15,797$74,516$54,420
Free Cash Flow-$1,987-$3,573-$3,522-$1,946
Oramed Pharmaceuticals Inc. (ORMP) Financial Statements & Key Stats | AlphaPilot